SE423545B - Analogiforfarande for framstellning av n-6-kloronikotinoyl-d,l-homocysteintiolakton - Google Patents
Analogiforfarande for framstellning av n-6-kloronikotinoyl-d,l-homocysteintiolaktonInfo
- Publication number
- SE423545B SE423545B SE7711347A SE7711347A SE423545B SE 423545 B SE423545 B SE 423545B SE 7711347 A SE7711347 A SE 7711347A SE 7711347 A SE7711347 A SE 7711347A SE 423545 B SE423545 B SE 423545B
- Authority
- SE
- Sweden
- Prior art keywords
- chloronicotinoyl
- preparation
- homocysteintiolacton
- compound
- homocysteine thiolactone
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- NGDJIWMBLGYWEG-UHFFFAOYSA-N 6-chloropyridine-3-carbonyl chloride;hydrochloride Chemical compound Cl.ClC(=O)C1=CC=C(Cl)N=C1 NGDJIWMBLGYWEG-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT51734/76A IT1068217B (it) | 1976-10-14 | 1976-10-14 | Omocisteina tiolattone 6 cloro nicotinamide |
Publications (2)
Publication Number | Publication Date |
---|---|
SE7711347L SE7711347L (sv) | 1978-04-15 |
SE423545B true SE423545B (sv) | 1982-05-10 |
Family
ID=11275646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE7711347A SE423545B (sv) | 1976-10-14 | 1977-10-10 | Analogiforfarande for framstellning av n-6-kloronikotinoyl-d,l-homocysteintiolakton |
Country Status (25)
Country | Link |
---|---|
US (1) | US4167572A (es) |
JP (1) | JPS5350178A (es) |
AR (1) | AR214527A1 (es) |
AT (1) | AT361925B (es) |
AU (1) | AU506922B2 (es) |
BE (1) | BE858443A (es) |
CA (1) | CA1078388A (es) |
CH (1) | CH629201A5 (es) |
DE (1) | DE2740345A1 (es) |
DK (1) | DK439277A (es) |
EG (1) | EG13219A (es) |
ES (1) | ES462110A1 (es) |
FI (1) | FI62303C (es) |
FR (1) | FR2367764A1 (es) |
GB (1) | GB1587273A (es) |
GR (1) | GR63598B (es) |
IE (1) | IE45365B1 (es) |
IN (1) | IN145767B (es) |
IT (1) | IT1068217B (es) |
NL (1) | NL7709938A (es) |
NO (1) | NO148714C (es) |
PH (1) | PH13068A (es) |
PT (1) | PT67155B (es) |
SE (1) | SE423545B (es) |
ZA (1) | ZA776157B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1215238B (it) * | 1985-02-22 | 1990-01-31 | Chiesi Farma Spa | Derivati di omocisteina tiolattone,loro procedimento di preparazione e formulazioni farmaceutiche |
WO1992000964A1 (en) * | 1990-07-05 | 1992-01-23 | Nippon Soda Co., Ltd. | Amine derivative |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1134683B (de) * | 1961-03-16 | 1962-08-16 | Degussa | Verfahren zur Herstellung von N-Acylhomocysteinthiolacton |
US4021433A (en) * | 1973-03-08 | 1977-05-03 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Derivative of nicotinic acid with amides |
IT1056031B (it) * | 1973-03-08 | 1982-01-30 | Sigma Tau Ind Farmaceuti | Redivati ammidici dell acido nicotininico |
-
1976
- 1976-10-14 IT IT51734/76A patent/IT1068217B/it active
-
1977
- 1977-08-05 IE IE1645/77A patent/IE45365B1/en unknown
- 1977-08-09 IN IN1234/CAL/77A patent/IN145767B/en unknown
- 1977-08-12 AU AU27868/77A patent/AU506922B2/en not_active Expired
- 1977-08-30 AR AR268995A patent/AR214527A1/es active
- 1977-09-03 ES ES462110A patent/ES462110A1/es not_active Expired
- 1977-09-06 CA CA286,093A patent/CA1078388A/en not_active Expired
- 1977-09-06 BE BE180705A patent/BE858443A/xx not_active IP Right Cessation
- 1977-09-07 DE DE19772740345 patent/DE2740345A1/de not_active Ceased
- 1977-09-09 NL NL7709938A patent/NL7709938A/xx not_active Application Discontinuation
- 1977-09-19 AT AT670977A patent/AT361925B/de not_active IP Right Cessation
- 1977-09-19 CH CH1140877A patent/CH629201A5/it not_active IP Right Cessation
- 1977-09-21 FR FR7728396A patent/FR2367764A1/fr active Granted
- 1977-09-28 US US05/837,529 patent/US4167572A/en not_active Expired - Lifetime
- 1977-10-04 DK DK439277A patent/DK439277A/da not_active Application Discontinuation
- 1977-10-07 JP JP12135877A patent/JPS5350178A/ja active Pending
- 1977-10-09 EG EG583/77A patent/EG13219A/xx active
- 1977-10-10 SE SE7711347A patent/SE423545B/sv unknown
- 1977-10-11 GR GR54549A patent/GR63598B/el unknown
- 1977-10-11 PH PH20325A patent/PH13068A/en unknown
- 1977-10-11 FI FI773001A patent/FI62303C/fi not_active IP Right Cessation
- 1977-10-13 NO NO773506A patent/NO148714C/no unknown
- 1977-10-14 PT PT67155A patent/PT67155B/pt unknown
- 1977-10-14 GB GB42890/77A patent/GB1587273A/en not_active Expired
-
1978
- 1978-05-23 ZA ZA00776157A patent/ZA776157B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NO773506L (no) | 1978-04-17 |
US4167572A (en) | 1979-09-11 |
FR2367764B1 (es) | 1980-09-05 |
NO148714B (no) | 1983-08-22 |
NO148714C (no) | 1983-11-30 |
PT67155B (fr) | 1979-03-19 |
CA1078388A (en) | 1980-05-27 |
IN145767B (es) | 1978-12-16 |
SE7711347L (sv) | 1978-04-15 |
BE858443A (fr) | 1978-01-02 |
ES462110A1 (es) | 1978-06-01 |
NL7709938A (nl) | 1978-04-18 |
DK439277A (da) | 1978-04-15 |
AU506922B2 (en) | 1980-01-31 |
AU2786877A (en) | 1979-02-15 |
AT361925B (de) | 1981-04-10 |
IE45365B1 (en) | 1982-08-11 |
AR214527A1 (es) | 1979-06-29 |
GB1587273A (en) | 1981-04-01 |
FI62303B (fi) | 1982-08-31 |
PT67155A (fr) | 1977-11-01 |
JPS5350178A (en) | 1978-05-08 |
FR2367764A1 (fr) | 1978-05-12 |
FI62303C (fi) | 1982-12-10 |
ATA670977A (de) | 1980-09-15 |
EG13219A (en) | 1980-12-31 |
GR63598B (en) | 1979-11-26 |
ZA776157B (en) | 1978-07-26 |
IE45365L (en) | 1978-04-14 |
FI773001A (fi) | 1978-04-15 |
DE2740345A1 (de) | 1978-04-20 |
CH629201A5 (it) | 1982-04-15 |
PH13068A (en) | 1979-11-23 |
IT1068217B (it) | 1985-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170362182A1 (en) | Multiple-component solid phases containing at least one active pharmaceutical ingredient | |
SU577983A3 (ru) | Способ получени 2-тетрагидрофурфурил-6,7-бензоморфанов или их солей, рацематов или оптически активных антиподов | |
Lemmerer et al. | Synthesis characterization molecular modeling of a pharmaceutical co-crystal:(2-chloro-4-nitrobenzoic acid):(nicotinamide) | |
JPS62503172A (ja) | アミノ酸誘導体 | |
JPS6155907B2 (es) | ||
JPH05502682A (ja) | ピペラジン誘導体 | |
JPH0159271B2 (es) | ||
CN107056699A (zh) | 一种高纯度顺苯磺酸阿曲库铵的制备方法 | |
EP0172029B1 (en) | 1,4-dihydropyridines | |
SE423545B (sv) | Analogiforfarande for framstellning av n-6-kloronikotinoyl-d,l-homocysteintiolakton | |
JPS59141558A (ja) | 2−イミノ−ピロリジン類,その製造法および治療用組成物 | |
DK141875B (da) | Analogifremgangsmaade til fremstilling af normorphinonderivater eller syreadditionssalte deraf | |
US5231095A (en) | S-timolol hemihydrate | |
SU1053749A3 (ru) | Способ получени 1,2-бис-(никотинамидо)-пропана или его солей с фармацевтически приемлемой кислотой | |
JPH0337549B2 (es) | ||
Kaliraj et al. | Design, synthesis of Dioxopiperidinamide derivatives by amide coupling reaction and study of their biological activity | |
NO752078L (es) | ||
US4088653A (en) | Tetrahydropyridyl derivatives | |
JPS61122288A (ja) | チエノピリジン誘導体、その製造法及びそれを含有する医薬組成物 | |
RU2004539C1 (ru) | Полистиролсульфонат 4-[3-[этил[-3-(пропилсульфинил)-пропил) амино)-2-оксипропокси]бензонитрила в виде смеси стереоизомеров или чистого стереоизомера, обладающий антиаритмическим действием | |
US9920045B2 (en) | Solid state forms of a PDE10 inhibitor | |
US4021433A (en) | Derivative of nicotinic acid with amides | |
JPH0211592A (ja) | 光学活性なジヒドロピリジンホスホン酸エステル | |
US4100289A (en) | Amidic derivatives of nicotinic acid as therapeutics | |
May | Structures Related to Morphine. VII. Piperidine Derivatives and Examples of Failure in Knoevenagel Reaction |